US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

iShares Core High Dividend ETF

117.04

-0.1169-0.10%

Volume:696.14K

Turnover:81.44M

Market Cap:10.97B

PE:- -

High:117.79

Open:117.40

Low:116.60

Close:117.16

Loading ...

Overview Company News Filings

Concept

ETF & Stock Investment+0.95%

Fractional Shares+0.95%

Capital Flow

Inflow:

Outflow:

News

Gilead to Present Latest Advancements Across Primary Biliary Cholangitis and Viral Hepatitis

Assembly Biosciences Presents New Data Highlighting Long-Acting Herpes Simplex Virus Candidate ABI-5366 and Genital Herpes Prevalence and Treatment Patterns at the 2025 ESCMID Congress

Press Release: Assembly Biosciences Reports Year End 2024 Financial Results and Recent Highlights

Vir Biotechnology Enrolls First Patient in Phase 3 ECLIPSE Registrational Program for Chronic Hepatitis Delta

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/HDV"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"HDV","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"HDV\",,,,,undefined,":{"symbol":"HDV","market":"US","secType":"STK","nameCN":"iShares Core High Dividend ETF","latestPrice":117.04,"timestamp":1750104000000,"preClose":117.15691,"halted":0,"volume":696139,"delay":0,"floatShares":93700000,"shares":93700000,"eps":0,"marketStatus":"Pre-Mkt","change":-0.11691,"latestTime":"06-17 06:55:03 EDT","open":117.4,"high":117.79,"low":116.595,"amount":81435906.53275,"amplitude":0.0102,"askPrice":129.16,"askSize":100,"bidPrice":112.8,"bidSize":3,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1750167000000},"marketStatusCode":1,"adr":0,"adrRate":0,"exchange":"ARCA","adjPreClose":117,"sharesOutstanding":93700000,"nav":118.052239,"aum":11061494794.3,"dividendRate":0.034684,"bidAskSpread":0.000297,"postHourTrading":{"tag":"盘后","latestPrice":117.04,"preClose":117.04,"latestTime":"19:41 EDT","volume":45,"amount":5261.74,"timestamp":1750117309507},"volumeRatio":2.3522039744704992,"impliedVol":0.0816,"impliedVolPercentile":0.1486},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"HDV\",,,,,undefined,":{"symbol":"HDV","floatShares":93700000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":2.3522039744704992,"shares":93700000,"dividePrice":4.059385,"high":117.79,"amplitude":0.0102,"preClose":117.15691,"low":116.595,"week52Low":106.005,"pbRate":"--","week52High":122.5,"institutionHeld":0,"latestPrice":117.04,"committee":-0.941748,"eps":0,"divideRate":0.034684,"volume":696139,"delay":0,"ttmEps":0,"open":117.4,"prevYearClose":112.26,"prevWeekClose":118.07,"prevMonthClose":116.29,"prevQuarterClose":121.12,"fiveDayClose":116.54,"twentyDayClose":116.56,"sixtyDayClose":119.32},"@#url:\"https://hq.skytigris.cn/market/plate/belongs/HDV\",params:#limit:6,delay:false,,,undefined,":[{"market":"US","name":"ETF & Stock Investment","bkCode":"BK4585","id":"package_us_concept_etf&gpdt","changeRate":0.0095},{"market":"US","name":"Fractional Shares","bkCode":"BK4588","id":"package_us_concept_sg","changeRate":0.009502}],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"HDV\",pageSize:4,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2531544753","title":"Gilead to Present Latest Advancements Across Primary Biliary Cholangitis and Viral Hepatitis","url":"https://stock-news.laohu8.com/highlight/detail?id=2531544753","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531544753?lang=en_us&edition=fundamental","pubTime":"2025-04-29 20:30","pubTimestamp":1745929800,"startTime":"0","endTime":"0","summary":"– New findings to be presented at the 2025 European Association for the Study of the Liver  Congress continue to demonstrate the effectiveness of Livdelzi  in reducing pruritus in people with primary biliary cholangitis  –。– Additional presentations will showcase the potential for maintained virologic response following treatment with investigational bulevirtide in people with hepatitis delta virus  –。– Presentations in hepatitis B virus  and hepatitis C virus  will underscore Gilead’s commitment to advancing scientific research and our understanding of viral hepatitis in the real-world setting –。In hepatitis B , Gilead will present initial results from a Phase 1a study of a nov","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/gilead-present-latest-advancements-across-123000497.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU2361045086.USD","IE00BQXX3D17.EUR","IE00BYQQ9H92.USD","LU1989772840.SGD","LU2317271919.USD","BK4534","LU0198837287.USD","LU0820561818.USD","LU0109394709.USD","LU2552382132.HKD","BK4533","IE00BFSS8Q28.SGD","LU0053666078.USD","EC","LU2054465674.USD","IE0005OL40V9.USD","GILD","LU2087625088.SGD","LU1366192091.USD","LU2420271590.USD","EEA","LU0494093205.USD","LU0056508442.USD","LU1430594728.SGD","MA","LU0107464264.USD","BK4548","LU0557290698.USD","BK4581","IE0004086264.USD","LU0417517546.SGD","IE00B19Z3581.USD","PRT","LU2106854487.HKD","LU2250418816.HKD","IE00B775H168.HKD","LU0011850046.USD","PBC","HDV","BK4559","TDF","IE00BKDWB100.SGD","LU1989764664.SGD","LU0708995401.HKD","LU1989772923.USD","LU1670627923.USD","BK4213","IE00B7SZLL34.SGD","LU2361044949.HKD","LU1989764748.USD"],"gpt_icon":0},{"id":"2526385370","title":"Assembly Biosciences Presents New Data Highlighting Long-Acting Herpes Simplex Virus Candidate ABI-5366 and Genital Herpes Prevalence and Treatment Patterns at the 2025 ESCMID Congress","url":"https://stock-news.laohu8.com/highlight/detail?id=2526385370","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526385370?lang=en_us&edition=fundamental","pubTime":"2025-04-09 14:00","pubTimestamp":1744178400,"startTime":"0","endTime":"0","summary":"– Clinical and preclinical data supporting dosing profile and tolerability for ABI-5366, a novel long-acting helicase-primase inhibitor candidate, featured in two poster presentations – – Additional p","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/04/09/3058117/16259/en/Assembly-Biosciences-Presents-New-Data-Highlighting-Long-Acting-Herpes-Simplex-Virus-Candidate-ABI-5366-and-Genital-Herpes-Prevalence-and-Treatment-Patterns-at-the-2025-ESCMID-Cong.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4218","BK4588","PK","BK4181","BK4585","ASMB","BK4139","HDV"],"gpt_icon":0},{"id":"2521496941","title":"Press Release: Assembly Biosciences Reports Year End 2024 Financial Results and Recent Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2521496941","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521496941?lang=en_us&edition=fundamental","pubTime":"2025-03-21 04:05","pubTimestamp":1742501100,"startTime":"0","endTime":"0","summary":"-- Four development candidates in clinical studies with data anticipated this year, continuing rapid progress of antiviral pipeline --. -- Interim Phase 1b proof-of-concept data, including initial efficacy measures, anticipated in fall 2025 for ABI-5366 and ABI-1179, long-acting helicase-primase inhibitor candidates for recurrent genital herpes --. SOUTH SAN FRANCISCO, Calif., March 20, 2025  -- Assembly Biosciences, Inc. , a biotechnology company developing innovative therapeutics targeting serious viral diseases, today reported financial results for the year ended December 31, 2024, and recent highlights.\"We are well-positioned to deliver important clinical data on four of our novel antiviral candidates in 2025, including proof-of-concept efficacy data expected this fall from the Phase 1b studies of ABI-5366 and ABI-1179 for recurrent genital herpes,\" said Jason Okazaki, chief executive officer and president of Assembly Bio. \"We anticipate that the rapid progress across our clinical ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PK","ASMB","HDV","BK4218","BK4181","BK4588","BK4585"],"gpt_icon":0},{"id":"2519836627","title":"Vir Biotechnology Enrolls First Patient in Phase 3 ECLIPSE Registrational Program for Chronic Hepatitis Delta","url":"https://stock-news.laohu8.com/highlight/detail?id=2519836627","media":"Business Wire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519836627?lang=en_us&edition=fundamental","pubTime":"2025-03-13 20:05","pubTimestamp":1741867500,"startTime":"0","endTime":"0","summary":"First patient enrolled in ECLIPSE 1 Phase 3 clinical trial evaluating combination of tobevibart and elebsiran for chronic suppressive treatment. Rapid study start indicative of significant unmet need for chronic hepatitis delta treatment. SAN FRANCISCO, March 13, 2025----Vir Biotechnology, Inc.  today announced the enrollment of the first patient in its Phase 3 ECLIPSE registrational program. The ECLIPSE registrational program is designed to evaluate the efficacy and safety of tobevibart in combination with elebsiran in people living with chronic hepatitis delta . ECLIPSE 1, the first trial of the program to be initiated, and ECLIPSE 2 are Phase 3 trials designed to provide the registrational data needed for submission to multiple regulatory agencies. ECLIPSE 3, a Phase 2b trial, is designed to provide important supportive data to help enable access and reimbursement strategies in key European markets.The significant unmet need in CHD and the potential for tobevibart and elebsir","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/vir-biotechnology-enrolls-first-patient-120500531.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1430594728.SGD","BK4585","CHD","BK4588","BK4504","BK4535","BK4568","BK4018","LU1585245621.USD","HDV","BK4139","VIR"],"gpt_icon":0}],"pageSize":4,"totalPage":4,"pageCount":1,"totalSize":13,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/HDV\",params:#limit:5,,,undefined,":[{"date":"2025-06-16","symbol":"HDV","amount":0.91309,"announcedDate":"2025-06-13","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-06-16","defaultRemindTime":1750080600000,"name":"iShares High Dividend Equity Fun","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-06-20","payableDate":"2025-06-16","currency":"USD","dateTimestamp":1750046400000,"payDate":"2025-06-20"},{"date":"2025-03-18","symbol":"HDV","amount":0.795075,"announcedDate":"2025-03-17","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-03-18","defaultRemindTime":1742304600000,"name":"iShares High Dividend Equity Fun","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-03-21","payableDate":"2025-03-18","currency":"USD","dateTimestamp":1742270400000,"payDate":"2025-03-21"},{"date":"2024-12-17","symbol":"HDV","amount":1.12172,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-12-17","defaultRemindTime":1734445800000,"name":"iShares High Dividend Equity Fun","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-12-20","payableDate":"2024-12-17","currency":"USD","dateTimestamp":1734411600000,"payDate":"2024-12-20"},{"date":"2024-09-25","symbol":"HDV","amount":1.2295,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-09-25","defaultRemindTime":1727271000000,"name":"iShares High Dividend Equity Fun","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-09-30","payableDate":"2024-09-25","currency":"USD","dateTimestamp":1727236800000,"payDate":"2024-09-30"},{"date":"2024-06-11","symbol":"HDV","amount":0.92835,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-06-11","defaultRemindTime":1718112600000,"name":"iShares High Dividend Equity Fun","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-06-17","payableDate":"2024-06-11","currency":"USD","dateTimestamp":1718078400000,"payDate":"2024-06-17"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"HDV\",market:\"US\",,,undefined,":[{"executeDate":"2015-06-24","recordDate":"2015-06-26","paymentDate":"2015-06-30","value":0.724784,"currency":"USD"},{"executeDate":"2015-09-25","recordDate":"2015-09-29","paymentDate":"2015-10-01","value":0.722168,"currency":"USD"},{"executeDate":"2015-12-24","recordDate":"2015-12-29","paymentDate":"2015-12-31","value":0.715673,"currency":"USD"},{"executeDate":"2016-03-23","recordDate":"2016-03-28","paymentDate":"2016-03-30","value":0.676805,"currency":"USD"},{"executeDate":"2016-06-21","recordDate":"2016-06-23","paymentDate":"2016-06-27","value":0.679421,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"HDV\",market:\"US\",delay:false,,,undefined,":{}}}